Two new gene therapies for sickle cell disease show striking results, but reaching patients may prove hard
The FDA approved Casgevy and Lyfgenia in December 2023, the first gene therapies for severe sickle cell disease. Trial results were strong, but high costs, complex procedures and uneven access to specialist centres could keep them out of reach for many of the 100,000 Americans living with the condition.
2 min read